Table 3.
Therapeutic regimen in IMN patients with and without coexisting DM
| Therapeutic regimen | Total (n = 206) |
Non-DM (n = 164) |
DM (n = 42) |
P-value |
|---|---|---|---|---|
| Non-Immunosuppressive therapy (n, %) | 54 (26.2) | 44 (26.8) | 10 (23.8) | 0.691 |
| Immunosuppressive therapy (n, %) | 152 (73.8) | 120 (73.2) | 32 (76.2) | |
| Glucocorticoids dosage (g) | 1.8 (1.8,2.7) | 1.8 (1.8,2.7) | 1.8 (1.9,3.4) | 0.586 |
| CTX (n, %) | 20 (9.7) | 12 (7.3) | 8 (19.0) | 0.037 |
| CsA (n, %) | 96 (46.6) | 76 (46.4) | 20 (47.6) | 0.882 |
| FK506 (n, %) | 23 (11.2) | 20 (12.2) | 3 (7.2) | 0.425 |
| Othera(n, %) | 13 (6.3) | 12 (7.3) | 1 (2.4) | 0.474 |
Data were expressed as numbers (%). All immunosuppressive therapy was combined with glucocorticoids
DM diabetes mellitus, CTX cyclophosphamide, CsA ciclosporin, FK506 tacrolimus
aother therapeutic regimens included mycophenolate mofetil and glucocorticoids, rituximab and glucocorticoids